{"id":15191,"date":"2021-04-05T09:59:46","date_gmt":"2021-04-05T07:59:46","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15191"},"modified":"2021-04-05T09:59:46","modified_gmt":"2021-04-05T07:59:46","slug":"une-nouvelle-formulation-en-sous-cutanee-pour-simplifier-ladministration-de-daratumumab","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/une-nouvelle-formulation-en-sous-cutanee-pour-simplifier-ladministration-de-daratumumab\/","title":{"rendered":"Une nouvelle formulation en sous-cutan\u00e9e pour simplifier l&#8217;administration de daratumumab"},"content":{"rendered":"<p>Avec l\u2019\u00e9tude de phase III COLUMBA : daratumumab en sous-cutan\u00e9e <em>vs<\/em>. daratumumab par voie<\/p>\n<p>intraveineuse et l\u2019\u00e9tude de phase II, en ouvert, PLEIADES, \u00a0les donn\u00e9es de ces \u00e9tudes ont conduit l\u2019Agence europ\u00e9enne des m\u00e9dicaments\u00e0 d\u00e9livrer une AMM en juin 2020 pour l\u2019utilisation de la formulation sous-cutan\u00e9e<\/p>\n<p>du daratumumab pour le traitement des patients atteints d\u2019un my\u00e9lome multiple. Il s\u2019applique \u00e0 toutes les indications actuelles du daratumumab, incluant les patients nouvellement diagnostiqu\u00e9s \u00e9ligibles ou non \u00e0 une autogreffe de cellules souches, les patients en rechute, et les patients ayant d\u00e9but\u00e9 un traitement avec le daratumumab par voie intraveineuse.<\/p>","protected":false},"excerpt":{"rendered":"<p>Avec l\u2019\u00e9tude de phase III COLUMBA : daratumumab en sous-cutan\u00e9e vs. daratumumab par voie intraveineuse et l\u2019\u00e9tude de phase II, en ouvert, PLEIADES, \u00a0les donn\u00e9es de ces \u00e9tudes ont conduit [&hellip;]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[1],"tags":[],"ppma_author":[442],"class_list":["post-15191","post","type-post","status-publish","format-standard","hentry","category-non-classe","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15191"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15191\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15191"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}